Business Context and Reporting Period
Company: Compugen Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: December 2011 (Specifically December 20, 2011)
Context: The filing discloses a new funding agreement entered into with an existing investor, Baize Investments (Israel) Ltd., to support research and development of therapeutic monoclonal antibody (mAb) product candidates.
Key Financial Metrics
The filing does not provide standard financial statements (revenue, profit, cash flow, or margins) for the period. The primary financial data relates to the new funding agreement:
- Total Investment Amount: $8,000,000
- Payment Schedule:
- $2,000,000 within 5 business days of the effective date.
- $3,000,000 on or before June 30, 2012.
- $3,000,000 on or before September 30, 2012.
- Debt/Liquidity Impact: The agreement provides future cash inflows contingent on payment milestones. No existing debt figures are disclosed in this text.
Material Changes and Transaction Details
The material change is the execution of the "Compugen Goldman Program" funding agreement with Baize Investments. Key terms include:
- Scope: Development of mAb product candidates against 12 specified oncology targets discovered by Compugen.
- Investor Return (Participation Interest): Baize receives a percentage of future payments from third-party out-licensing if candidates achieve successful animal disease models or are licensed within 3 years.
- Return Calculation: Based on a sliding scale relative to total research funding spent by Baize versus Compugen, with a guaranteed minimum of 10% of future payments for qualifying candidates.
- Default Provision: If Baize fails to make payments, Compugen may exchange the Participation Interest for Ordinary Shares at a fixed price of $6.00 per share, terminating future financial interests.
- Waiver Option: Baize has the right in Q1 2014 to waive the Participation Interest in exchange for 1,455,000 Compugen ordinary shares.
Guidance, Outlook, and Risks
Outlook: The funding is intended to advance the development of 12 oncology targets over a 3-year period. Success is contingent on achieving specific animal disease model milestones or securing third-party licenses.
Risks and Contingencies:
- Payment Risk: The full $8,000,000 is not guaranteed; it is subject to installment payments. Failure to pay triggers a conversion to equity at a fixed price.
- Dilution Risk: Potential issuance of up to 1,455,000 shares if Baize exercises its waiver option in 2014, or shares issued upon default of payments.
- Development Risk: The investor's return is contingent on scientific milestones (animal models) or commercial milestones (licensing), which are not guaranteed.
Investor Verification Checklist
- Verify the effective date of the agreement to confirm the timing of the initial $2,000,000 payment.
- Confirm the current cash position of Compugen to assess reliance on the remaining $6,000,000 in future installments.
- Review the specific 12 oncology targets to evaluate the scientific feasibility of the "successful animal disease model" milestone.
- Monitor the share price relative to the $6.00 default conversion price to understand potential dilution scenarios.
- Check for the future filing of the full Agreement text as promised in the explanatory note.